This is a critical observation: the 24.2% weight loss at 48 weeks was not the maximum achievable with continued treatment
Safety is insufficiently characterized
Candida infections of medical devices
HbA1c reductions up to 1.6 percentage points Weight trajectory: Weight loss had not plateaued by 52 weeks, indicating potential for further reduction with continued treatment Cardiometabolic: Improvements in waist circumference, blood pressure, hs-CRP, and lipid parameters Evidence level: Moderate -- well-designed phase 2 with NEJM publication, but single trial, no head-to-head comparisons
Moreover, its expression appears to be influenced by metabolic stress, with it being increased in islets from diet-induced obese mice compared to normal weight animals (104), but lower in human islets from diabetic compared to non-diabetic donors (98, 99, 104)
You cannot see denaturation